Anaplastic lymphoma kinase (ALK) fusion oncogene positive non small cell lung cancer
Updates to Article Attributes
Anaplastic lymphoma kinase (ALK) fusion oncogene positive non small cell lung cancer refers to a specific set of non small cell lung cancers that contain an inversion in chromosome 2.
They are associated with specific clinical features, including never or light smoking history, younger age, and adenocarcinoma with a signet ring or acinar histology.
Epidemiology
It may account for found in approximately 4-5 % of non small cell lung cancercancers.
Pathology
They resulting in the novel fusion oncogene EML4-ALK rearrangement is transforming both in vitro and in vivo and defines a distinct clinicopathologic subset of NSCLC. ALK gene arrangements are "largely but not entirely" mutually exclusive with epidermal growth factor receptor (EGFR) and KRAS mutations 6.
Radiographic features
Since it is a new discorverydiscovery there are not many imaging publications on this topic (i.e. one one or two studies per finding).
Some Some reported features include:
- more central tumour location 1
- absence of pleural tail 1
- associated large pleural effusion 1
- relatively smaller size 2
- lower tumour disappearance rate (TDR) rate following treatment 2
- may appear as more solid masses with lobulated margins 4
Treatment and prognosis
They are more responsive to anaplastic lymphoma kinase (ALK) and c-Met receptor kinases such as Crizotinibcrizotinib.
-<p><strong>Anaplastic lymphoma kinase (ALK) fusion oncogene positive non small cell lung cancer</strong> refers to a specific set of <a href="/articles/non-small-cell-lung-cancer-2">non small cell lung cancers</a> that contain an inversion in chromosome 2.</p><p>They are associated with specific clinical features, including never or light smoking history, younger age, and adenocarcinoma with signet ring or acinar histology. </p><h4>Epidemiology</h4><p> It may account for found in approximately 4-5 % of non small cell lung cancer.</p><h4>Pathology</h4><p>They resulting in the novel fusion oncogene <em>EML4-ALK</em> rearrangement is transforming both in vitro and in vivo and defines a distinct clinicopathologic subset of NSCLC. <em>ALK</em> gene arrangements are "largely but not entirely" mutually exclusive with epidermal growth factor receptor (<em>EGFR</em>) and <em>KRAS</em> mutations<sup> 6</sup>.</p><h4>Radiographic features</h4><p>Since it is new discorvery there are not many imaging publications on this topic (i.e. one one or two studies per finding) .</p><p>Some reported features include</p><ul>- +<p><strong>Anaplastic lymphoma kinase (ALK) fusion oncogene positive non small cell lung cancer</strong> refers to a specific set of <a href="/articles/non-small-cell-lung-cancer-2">non small cell lung cancers</a> that contain an inversion in chromosome 2. They are associated with specific clinical features, including never or light smoking history, younger age, and adenocarcinoma with a signet ring or acinar histology. </p><h4>Epidemiology</h4><p> It may account for 4-5 % of non small cell lung cancers.</p><h4>Pathology</h4><p>They resulting in the novel fusion oncogene <em>EML4-ALK</em> rearrangement is transforming both in vitro and in vivo and defines a distinct clinicopathologic subset of NSCLC. <em>ALK</em> gene arrangements are "largely but not entirely" mutually exclusive with epidermal growth factor receptor (<em>EGFR</em>) and <em>KRAS</em> mutations<sup> 6</sup>.</p><h4>Radiographic features</h4><p>Since it is a new discovery there are not many imaging publications on this topic (i.e. one or two studies per finding). Some reported features include:</p><ul>
-</ul><h4>Treatment and prognosis</h4><p>They are more responsive to anaplastic lymphoma kinase (ALK) and c-Met receptor kinases such as Crizotinib.</p>- +</ul><h4>Treatment and prognosis</h4><p>They are more responsive to anaplastic lymphoma kinase (ALK) and c-Met receptor kinases such as crizotinib.</p>
Tags changed:
- cases
Sections changed:
Systems changed:
- Oncology